Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics.
Acute heart failure
Antibody
Biomarkers
Immunotherapy
Procizumab
cDPP3
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
22
07
2019
revised:
01
08
2019
accepted:
05
08
2019
pubmed:
1
9
2019
medline:
19
5
2021
entrez:
1
9
2019
Statut:
ppublish
Résumé
Acute heart failure is a high mortality disease and its pathophysiology is not completely understood. Dipeptidyl peptidase 3 (DPP3) is a cytosolic enzyme involved in angiotensin II and enkephalins cleavage. The aim of this study was to investigate the association of circulating DPP3 (cDPP3) levels and mortality in cardiogenic shock patients and to determine the effects of high cDPP3 on organ function in a heart failure (HF) model in mice. cDPP3 was measured in 174 patients in cardiogenic shock and high cDPP3 levels were associated with an increased short-term mortality risk (standardized hazard ratio: 1.4 (1.1-1.8)) and severe organ dysfunction. Additionally, a rapid decrease in cDPP3 in cardiogenic shock patients within 24 h of admission was associated with a favourable outcome. This study showed that injection of DPP3 induced myocardial depression (-10 ± 2% of shortening fraction) and impaired kidney haemodynamics (+0.30 ± 0.02 of renal resistive index) in healthy mice. cDPP3 inhibition by Procizumab, a specific antibody directed against cDPP3, promptly normalized cardiac function and kidney haemodynamics in an acute heart failure mouse model, with a marked reduction in oxidative stress and inflammatory signalling. Our study demonstrated cDPP3 is a newly discovered myocardial depressant factor, the levels of which at admission are associated with mortality in severe HF patients. Furthermore, inhibition of cDPP3 by Procizumab improved haemodynamics in a mouse model of HF. Our results suggest that DPP3 could be a new biomarker and biotarget for severe HF.
Substances chimiques
Anti-Arrhythmia Agents
0
Antibodies, Monoclonal, Humanized
0
Biomarkers
0
procizumab
0
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
EC 3.4.14.-
DPP3 protein, human
EC 3.4.14.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-299Subventions
Organisme : Aarne Koskelo Foundation
Pays : International
Organisme : Finnish Cardiac Foundation
Pays : International
Organisme : Investitionsbank des Landes Brandenburg (ILB)
Pays : International
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.
Références
Braunwald E. Heart failure. JACC Heart Fail 2013;1:1-20.
Gutierrez E, Flammer AJ, Lerman LO, Elizaga J, Lerman A, Fernandez-Aviles F. Endothelial dysfunction over the course of coronary artery disease. Eur Heart J 2013;34:3175-3181.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-e239.
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure. J Am Coll Cardiol 2014;63:1123-1133.
Zhan H, Yamamoto Y, Shumiya S, Kunimatsu M, Nishi K, Ohkubo I, Kani K. Peptidases play an important role in cataractogenesis: an immunohistochemical study on lenses derived from Shumiya cataract rats. Histochem J 2001;33:511-521.
Prajapati SC, Chauhan SS. Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. FEBS J 2011;278:3256-3276.
Pang X, Shimizu A, Kurita S, Zankov DP, Takeuchi K, Yasuda-Yamahara M, Kume S, Ishida T, Ogita H. Novel therapeutic role for dipeptidyl peptidase III in the treatment of hypertension. Hypertension 2016;68:630-641.
Dale CS, Pagano RL, Rioli V. Hemopressin: a novel bioactive peptide derived from the alpha1-chain of hemoglobin. Mem Inst Oswaldo Cruz 2005;100:105-106.
Rehfeld L, Funk E, Jha S, Macheroux P, Melander O, Bergmann A. Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples. J Appl Lab Med November 2018. doi: 10.1373/jalm.2018.027995.
Harjola V-P, Lassus J, Sionis A, Køber L, Tarvasmäki T, Spinar J, Parissis J, Banaszewski M, Silva-Cardoso J, Carubelli V, Di Somma S, Tolppanen H, Zeymer U, Thiele H, Nieminen MS, Mebazaa A; CardShock Study Investigators; GREAT Network. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail 2015;17:501-509.
Kaufman P, Muenzner M, Kästorf M, Santos K, Hartmann T, Dienelt A, Rehfeld L, Bergman A. A novel and highly efficient two-step purification procedure for native human dipeptidyl peptidase 3 from human blood cell lysate. PLoS One 2019;14:e0220866.
Vergaro G, Prud'homme M, Fazal L, Merval R, Passino C, Emdin M, Samuel J-L, Cohen Solal A, Delcayre C. Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension 2016;67:606-612.
Bloom S, Davis DL. Calcium as mediator of isoproterenol-induced myocardial necrosis. Am J Pathol 1972;69:459-470.
Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and diastolic dysfunction in mice: structural and functional correlates. Comp Med 2009;59:339-343.
Hasić S, Jadrić R, Kiseljaković E, Mornjaković Z, Winterhalter-Jadrić M. Troponin T and histological characteristics of rat myocardial infarction induced by isoproterenol. Bosn J Basic Med Sci 2007;7:212-217.
Thiele H, Zeymer U, Neumann F-J, Ferenc M, Olbrich H-G, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Böhm M, Ebelt H, Schneider S, Schuler G, Werdan K; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012;367:1287-1296.
Kumar P, Reithofer V, Reisinger M, Wallner S, Pavkov-Keller T, Macheroux P, Gruber K. Substrate complexes of human dipeptidyl peptidase III reveal the mechanism of enzyme inhibition. Sci Rep 2016;6:23787.
Takagi K, Blet A, Levy B, Deniau B, Azibani F, Féliot E, Bergman A, Rehfeld L, Santos K, Dienelt A, Hartmann O, Mebazaa A, Kimmoun A. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. Eur J Heart Fail 2020;22:279-286.
Cingolani HE, Villa-Abrille MC, Cornelli M, Nolly A, Ennis IL, Garciarena C, Suburo AM, Torbidoni V, Correa MV, Camiliónde Hurtado MC, Aiello EA. The positive inotropic effect of angiotensin II: role of endothelin-1 and reactive oxygen species. Hypertension 2006;47:727-734.
Kobayashi M, Furukawa Y, Chiba S. Positive chronotropic and inotropic effects of angiotension II in the dog heart. Eur J Pharmacol 1978;50:17-25.